These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32536046)

  • 1. Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?
    Kim SY
    Clin Mol Hepatol; 2020 Jul; 26(3):309-311. PubMed ID: 32536046
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging.
    Choi SH; Byun JH; Lim YS; Yu E; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2016 May; 64(5):1099-1107. PubMed ID: 26820629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [5. Inspection of Hepatocellular Carcinoma 3-Contrast for the Diagnosis of Hepatocellular Carcinoma: Techniques of Image Contrast and the Choice of MR Contrast Agent].
    Kitoh Y
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2016 May; 72(5):441-51. PubMed ID: 27211090
    [No Abstract]   [Full Text] [Related]  

  • 4. Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents.
    Choi SH; Kim SY; Lim YS
    J Hepatol; 2020 Sep; 73(3):714-715. PubMed ID: 32546401
    [No Abstract]   [Full Text] [Related]  

  • 5. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm.
    Renzulli M; Biselli M; Brocchi S; Granito A; Vasuri F; Tovoli F; Sessagesimi E; Piscaglia F; D'Errico A; Bolondi L; Golfieri R
    Gut; 2018 Sep; 67(9):1674-1682. PubMed ID: 29437912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reply to: "Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents".
    Paisant A; Vilgrain V; Aubé C
    J Hepatol; 2020 Sep; 73(3):716-717. PubMed ID: 32546402
    [No Abstract]   [Full Text] [Related]  

  • 7. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA.
    Jung G; Breuer J; Poll LW; Koch JA; Balzer T; Chang S; Mödder U
    Acta Radiol; 2006 Feb; 47(1):15-23. PubMed ID: 16498928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gd-DTPA-DeA: a novel, liver-specific MRI contrast agent.
    Kawamura Y
    Acad Radiol; 2002 May; 9 Suppl 1():S102-3. PubMed ID: 12019839
    [No Abstract]   [Full Text] [Related]  

  • 9. Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease.
    Lee SE; An C; Hwang SH; Choi JY; Han K; Kim MJ
    Eur Radiol; 2018 Apr; 28(4):1551-1559. PubMed ID: 29134355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast-enhanced MRI of focal liver tumors using a hepatobiliary MR contrast agent: detection and differential diagnosis using Gd-EOB-DTPA-enhanced versus Gd-DTPA-enhanced MRI in the same patient.
    Hammerstingl R; Zangos S; Schwarz W; Rosen T; Bechstein WO; Balzer T; Vogl TJ
    Acad Radiol; 2002 May; 9 Suppl 1():S119-20. PubMed ID: 12019845
    [No Abstract]   [Full Text] [Related]  

  • 11. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma.
    Kobayashi T; Aikata H; Hatooka M; Morio K; Morio R; Kan H; Fujino H; Fukuhara T; Masaki K; Ohno A; Naeshiro N; Nakahara T; Honda Y; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Hyogo H; Takahashi S; Chayama K
    Eur Radiol; 2015 Nov; 25(11):3272-81. PubMed ID: 26037713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Application of Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the Diagnosis of Chronic Liver Disease-Induced Hepatocellular Carcinoma: A Meta-Analysis.
    Li X; Li C; Wang R; Ren J; Yang J; Zhang Y
    PLoS One; 2015; 10(12):e0144247. PubMed ID: 26629904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GADOXETATE DISODIUM (GD-EOB-DTPA) CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING CHARACTERISTICS OF HEPATOCELLULAR CARCINOMA IN DOGS.
    Constant C; Hecht S; Craig LE; Lux CN; Cannon CM; Conklin GA
    Vet Radiol Ultrasound; 2016 Nov; 57(6):594-600. PubMed ID: 27633531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI: initial experience.
    Lee SA; Lee CH; Jung WY; Lee J; Choi JW; Kim KA; Park CM
    Magn Reson Imaging; 2011 Jan; 29(1):83-90. PubMed ID: 20832227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma?
    Kudo M
    Oncology; 2010 Jul; 78 Suppl 1():87-93. PubMed ID: 20616589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study.
    Granito A; Galassi M; Piscaglia F; Romanini L; Lucidi V; Renzulli M; Borghi A; Grazioli L; Golfieri R; Bolondi L
    Aliment Pharmacol Ther; 2013 Feb; 37(3):355-63. PubMed ID: 23199022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging.
    Watcharin W; Schmithals C; Pleli T; Köberle V; Korkusuz H; Huebner F; Zeuzem S; Korf HW; Vogl TJ; Rittmeyer C; Terfort A; Piiper A; Gelperina S; Kreuter J
    Eur J Pharm Biopharm; 2014 May; 87(1):132-41. PubMed ID: 24365328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: Gadoxetic acid disodium.
    Rao SX; Wang J; Wang J; Jiang XQ; Long LL; Li ZP; Li ZL; Shen W; Zhao XM; Hu DY; Zhang HM; Zhang L; Huan Y; Liang CH; Song B; Zeng MS
    J Dig Dis; 2019 Feb; 20(2):54-61. PubMed ID: 30693659
    [No Abstract]   [Full Text] [Related]  

  • 19. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health economic evaluation of Gd-EOB-DTPA MRI vs ECCM-MRI and multi-detector computed tomography in patients with suspected hepatocellular carcinoma in Thailand and South Korea.
    Lee JM; Kim MJ; Phongkitkarun S; Sobhonslidsuk A; Holtorf AP; Rinde H; Bergmann K
    J Med Econ; 2016 Aug; 19(8):759-68. PubMed ID: 27026278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.